Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice

Paula L McClean, Jaishree Jalewa, Christian Hölscher

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Type 2 diabetes is a risk factor for Alzheimer's disease (AD). Previously, we have shown that the diabetes drug liraglutide is protective in middle aged and in old APP/PS1 mice. Here, we show that liraglutide has prophylactic properties. When injecting liraglutide once-daily ip. in two months old mice for 8 months, the main hallmarks of AD were much reduced. Memory formation in object recognition and Morris water maze were normalised and synapse loss and the loss of synaptic plasticity was prevented. In addition, amyloid plaque load, including dense core congophilic plaques, was much reduced. Chronic inflammation (activated microglia) was also reduced in the cortex, and neurogenesis was enhanced in the dentate gyrus. The results demonstrate that liraglutide may protect from progressive neurodegeneration that develops in AD. The drug is currently in clinical trials in patients with AD.
LanguageEnglish
Pages96-106
JournalBehavioural Brain Research
Volume293
DOIs
Publication statusAccepted/In press - 6 Jul 2015

Fingerprint

Amyloid Plaques
Alzheimer Disease
Inflammation
Neuronal Plasticity
Neurogenesis
Dentate Gyrus
Microglia
Therapeutics
Pharmaceutical Preparations
Synapses
Type 2 Diabetes Mellitus
Clinical Trials
Liraglutide
Water

Keywords

  • memory loss
  • synaptic loss
  • growth factor
  • insulin
  • incretin
  • LTP

Cite this

@article{8824687ef4464e5e8c388254bf7c1fe7,
title = "Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice",
abstract = "Type 2 diabetes is a risk factor for Alzheimer's disease (AD). Previously, we have shown that the diabetes drug liraglutide is protective in middle aged and in old APP/PS1 mice. Here, we show that liraglutide has prophylactic properties. When injecting liraglutide once-daily ip. in two months old mice for 8 months, the main hallmarks of AD were much reduced. Memory formation in object recognition and Morris water maze were normalised and synapse loss and the loss of synaptic plasticity was prevented. In addition, amyloid plaque load, including dense core congophilic plaques, was much reduced. Chronic inflammation (activated microglia) was also reduced in the cortex, and neurogenesis was enhanced in the dentate gyrus. The results demonstrate that liraglutide may protect from progressive neurodegeneration that develops in AD. The drug is currently in clinical trials in patients with AD.",
keywords = "memory loss, synaptic loss, growth factor, insulin, incretin, LTP",
author = "McClean, {Paula L} and Jaishree Jalewa and Christian H{\"o}lscher",
year = "2015",
month = "7",
day = "6",
doi = "10.1016/j.bbr.2015.07.024",
language = "English",
volume = "293",
pages = "96--106",
journal = "Behavioural Brain Research",
issn = "0166-4328",
publisher = "Elsevier",

}

Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice. / McClean, Paula L; Jalewa, Jaishree; Hölscher, Christian.

In: Behavioural Brain Research, Vol. 293, 06.07.2015, p. 96-106.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice

AU - McClean, Paula L

AU - Jalewa, Jaishree

AU - Hölscher, Christian

PY - 2015/7/6

Y1 - 2015/7/6

N2 - Type 2 diabetes is a risk factor for Alzheimer's disease (AD). Previously, we have shown that the diabetes drug liraglutide is protective in middle aged and in old APP/PS1 mice. Here, we show that liraglutide has prophylactic properties. When injecting liraglutide once-daily ip. in two months old mice for 8 months, the main hallmarks of AD were much reduced. Memory formation in object recognition and Morris water maze were normalised and synapse loss and the loss of synaptic plasticity was prevented. In addition, amyloid plaque load, including dense core congophilic plaques, was much reduced. Chronic inflammation (activated microglia) was also reduced in the cortex, and neurogenesis was enhanced in the dentate gyrus. The results demonstrate that liraglutide may protect from progressive neurodegeneration that develops in AD. The drug is currently in clinical trials in patients with AD.

AB - Type 2 diabetes is a risk factor for Alzheimer's disease (AD). Previously, we have shown that the diabetes drug liraglutide is protective in middle aged and in old APP/PS1 mice. Here, we show that liraglutide has prophylactic properties. When injecting liraglutide once-daily ip. in two months old mice for 8 months, the main hallmarks of AD were much reduced. Memory formation in object recognition and Morris water maze were normalised and synapse loss and the loss of synaptic plasticity was prevented. In addition, amyloid plaque load, including dense core congophilic plaques, was much reduced. Chronic inflammation (activated microglia) was also reduced in the cortex, and neurogenesis was enhanced in the dentate gyrus. The results demonstrate that liraglutide may protect from progressive neurodegeneration that develops in AD. The drug is currently in clinical trials in patients with AD.

KW - memory loss

KW - synaptic loss

KW - growth factor

KW - insulin

KW - incretin

KW - LTP

U2 - 10.1016/j.bbr.2015.07.024

DO - 10.1016/j.bbr.2015.07.024

M3 - Article

VL - 293

SP - 96

EP - 106

JO - Behavioural Brain Research

T2 - Behavioural Brain Research

JF - Behavioural Brain Research

SN - 0166-4328

ER -